Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

With Hormone Therapy, Tender Breasts May Signal Cancer Risk

Symptom might warrant a reassessment of treatment, experts suggest

By Jennifer Thomas
HealthDay Reporter


Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
Amenorrhea
Amniocentesis
Amniocentesis and CVS
More...

Related Healthscout Videos
 border=
Optimistic Healing
Early Babies: How Soon is Too Soon?
Aqua Lipo
Cancer Treatment for Any Size
More...

Related Animations
 border=
Breast Reduction
Breast Self-Exam Video
Colon Cancer
Erectile Dysfunction
More...

Related Drug Information
 border=
Actonel
Detrol LA
Diflucan
Ditropan XL
More...

Related News Articles
 border=
Diet Soda and Salt: Destroying your Kidneys?
Folate Levels in Pregnancy Tied to ADHD in Offspring
CDC Study Links 2 Antibiotics to Birth Defects
Switch to 'Light' Cigarettes Makes Quitting Tougher
More...

MONDAY, Oct. 12 (HealthDay News) -- Breast tenderness in women taking estrogen/progestin hormone replacement therapy could signal increased chances of developing breast cancer, a new study says.

Women taking estrogen plus progestin who reported developing breast tenderness after starting the hormone therapy were 48 percent more likely to develop invasive breast cancer than women on hormone therapy who did not experience breast tenderness.

Text Continues Below



Researchers said more study is needed before they would recommend that women who experience this symptom discontinue taking the hormones. But women who develop breast tenderness might want to reassess if the hormones are really necessary to control their menopausal symptoms.

"It's too soon to tell women to quit their hormone therapy, but it is something for women to think about in balancing the risks versus the benefits," said the study's lead author, Dr. Carolyn J. Crandall, a clinical professor of general internal medicine and health services research at the David Geffen School of Medicine at the University of California, Los Angeles.

"Breast tenderness is a symptom that may be a risk marker for breast cancer," she said.

The study is in the Oct. 12 issue of the Archives of Internal Medicine.

Researchers used data from the Women's Health Initiative, a landmark federal study that was halted in 2002 after investigators determined that hormone replacement therapy increased the risk for heart attack, stroke and invasive breast cancer.

Since then, most women have been advised to use hormone replacement therapy -- which physicians now call menopausal hormone therapy -- either not at all or for the shortest duration possible to get them through their most uncomfortable menopausal symptoms, usually hot flashes, Crandall said. Women are strongly advised to avoid taking hormones for longer than five years, when the risk for breast cancer doubles.

Page:  1 | 2 | 3 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 10/12/2009

Related Links
 border=
From Healthscout's partner site on breast cancer, MyBreastCancerNetwork.com
VIDEO: Chemo booster cuts treatment time by two months
SYMPTOMS: Learn what to look for and what the symptoms mean
PROGNOSIS: Early detection and new treatments improve survival rates





SOURCES: Carolyn Crandall, M.D., clinical professor, general internal medicine and health services research, David Geffen School of Medicine, University of California, Los Angeles, and faculty member, Iris Cantor-UCLA Women's Health Center; Mary B. Daly, M.D., Ph.D., director, Personalized Cancer Risk Assessment Program, Fox Chase Cancer Center, Philadelphia; Oct. 12, 2009, news statement, Wyeth Pharmaceuticals; Oct. 12, 2009, Archives of Internal Medicine


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy